Objective:

To evaluate the efficacy and safety of vamikibart, an IL-6 targeting molecule, in treating uveitic macular edema.

Approach:

Key Findings:

• Patients treated with vamikibart improved visual acuity by about 10 letters compared to 3-4 letters with sham.
• Vamikibart reduced retinal anatomy by approximately 200 µm.
• Both doses showed a good safety profile with low rates of intraocular inflammation, cataract, and intraocular pressure.

Interpretation:

Vamikibart demonstrates promising efficacy and safety in treating uveitic macular edema, with potential for longer-lasting effects due to IL-6 suppression.

Limitations:

• The 1 mg dose in SANDCAT did not reach statistical significance.
• Full-year data is still pending for further evaluation.

Conclusion:

Vamikibart represents a new treatment option for uveitic macular edema, potentially offering a safer alternative to steroids with less injection burden.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.